← Back to Search

Vasodilator

aFFR vs cFFR for Percutaneous Coronary Intervention (ACCELERATION Trial)

Phase 4

Waitlist Available

Led By Rajesh Swaminathan, MD

Research Sponsored by Duke University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

ACCELERATION Trial Summary

This trial will compare two methods of measuring FFR, where one method uses a contrast agent injected through an automated injector. The goal is to see if the automated injector is associated with long-term clinical outcomes.

ACCELERATION Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison Between Contrast Fractional Flow Reserves (cFFR) and Adenosine Fractional Flow Reserves (aFFR)

Qualitative Method Comparison Between Contrast Fractional Flow Reserves and Adenosine Fractional Flow Reserves

Secondary outcome measures

Assessment of the Relationship Between Post-Percutaneous Coronary Intervention Fractional Flow Reserves and Long-Term Clinical Outcomes

ACCELERATION Trial Design

1Treatment groups

Experimental Treatment

Group I: aFFR vs cFFRExperimental Treatment4 Interventions

All subjects will receive Fractional Flow Reserve Measurements with both adenosine (aFFR) and contrast (Iopamidol) (cFFR) using the Navvus® Catheter and CVi® Contrast Delivery System

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Iopamidol

2017

Completed Phase 4

~1160

CVi® Contrast Delivery System

2019

Completed Phase 4

~210

adenosine

2020

Completed Phase 4

~2120

Navvus® Catheter

2019

Completed Phase 4

~210

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor

2,363 Previous Clinical Trials

3,420,285 Total Patients Enrolled

Acist Medical SystemsIndustry Sponsor

6 Previous Clinical Trials

2,317 Total Patients Enrolled

Rajesh Swaminathan, MDPrincipal InvestigatorDCRI

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any Canadian sites hosting this research endeavor?

"The University of Minnesota in Minneapolis, Long Beach VA in Long Beach, and Mercy Hospital in Coon Rapids are just three of the five trial sites currently operating. Two additional locations have been selected for this research initiative as well."

Answered by AI

What medical ailments can this medication be utilized to address?

"Myocardial scintigraphy is a common application for this medication, yet it can additionally be prescribed to treat coronary artery disease (CAD), pulmonary arterial hypertension, and supraventricular tachycardia."

Answered by AI

How many participants are involved with this clinical research?

"At this juncture, enrolment for the clinical trial is suspended. It was initially posted in January of 2019 and last modified on July 27th 2022. Presently, there are 50 studies searching for people with percutaneous coronary intervention (PCI) and 12 trials that are actively taking patients into their program."

Answered by AI

Are there any risks associated with this medical intervention?

"Data from the Phase 4 trial of this treatment demonstrates its safety, awarding it a score of 3."

Answered by AI

What other research initiatives have been undertaken to investigate this therapeutic approach?

"Initially researched at Centre Hospitalier de Compiègne in 2011, this treatment has been the subject of 55 completed clinical trials. Currently, 12 active studies are recruiting participants, with a significant portion conducted from Minneapolis in Minnesota."

Answered by AI

Is this research project still open to applicants?

"The information posted on clinicaltrials.gov suggests that the recruitment process for this medical study has been concluded, with its first post dating back to January 17th 2019 and its last update occurring on July 27th 2022. Despite not being able to join this trial, there are presently 62 other studies actively seeking participants."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

2019. "Adenosine Contrast CorrELations in Evaluating RevAscularizaTION". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03557385.